Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Cancer cachexia is a multifaceted metabolic syndrome characterized by severe loss of skeletal muscle and adipose tissue, diminishing both quality of life and survival in cancer patients. Despite its prevalence, effective treatments for cancer cachexia remain limited. The JAK/STAT signaling...

๐Ÿ—“๏ธ 2025-07-03
๐Ÿ“ฐ Publication: Journal Of Advanced Research
Read MoreScutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway.

Aging induces sarcopenia by disrupting the crosstalk between the skeletal muscle microenvironment and myofibers.

Sarcopenia is a degenerative muscular disease associated with aging, characterized by a reduction in muscle mass and strength. This disease poses a significant global health challenge, owing to its high prevalence and association with adverse outcomes such as increased frailty,...

๐Ÿ—“๏ธ 2025-07-03
๐Ÿ“ฐ Publication: Journal Of Advanced Research
Read MoreAging induces sarcopenia by disrupting the crosstalk between the skeletal muscle microenvironment and myofibers.

Pancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.

Pancreatic ductal adenocarcinoma (PDAC) with cachexia-related muscle wasting as the main manifestation is associated with poor overall survival. Extracellular vesicles (EVs) are key mediators of inter-organ communication. Here, EVs and EV-microRNAs (miRNAs) are identified as mediate PDAC-skeletal muscle communication. EVs...

๐Ÿ—“๏ธ 2025-07-02
Read MorePancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia.

Clarification and standardization of dual-energy X-ray absorptiometry terminology for accurate scientific communication and clinical diagnostic accuracy.

The evaluation of skeletal muscle (SM) mass has significant clinical and research relevance in the diagnosis and management of conditions such as malnutrition, sarcopenia, sarcopenic obesity, and cancer cachexia. Dual-energy X-ray absorptiometry (DXA) is now the most widely used method...

๐Ÿ—“๏ธ 2025-06-30
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreClarification and standardization of dual-energy X-ray absorptiometry terminology for accurate scientific communication and clinical diagnostic accuracy.

Histidine decarboxylase inhibition attenuates cancer-associated muscle wasting.

Cancer cachexia is a multifactorial syndrome involving muscle and fat wasting, inflammation, and metabolic dysfunction. Across cancer subtypes, pancreatic cancer has one of the highest cachexia incidence rates at โˆผ80%. Given the advanced age of most pancreatic cancer patients, we...

๐Ÿ—“๏ธ 2025-07-02
๐Ÿ“ฐ Publication: Journal Of Experimental Medicine
Read MoreHistidine decarboxylase inhibition attenuates cancer-associated muscle wasting.

Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine.

Sarcopenia, a progressive decline in skeletal muscle mass and function, has emerged as a critical geriatric syndrome affecting 10-40% of older adults, contributing to increased disability and mortality. This comprehensive review evaluates evidence-based strategies for sarcopenia management, from established interventions...

๐Ÿ—“๏ธ 2025-06-11
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreTherapeutic advances in sarcopenia management: From traditional interventions to personalized medicine.

The association of n-3 fatty acid intake with muscle mass and strength in older adults: A cross-sectional analysis of the UK biobank data.

The main aim was to investigate the association of n-3 fatty acid intake and the n-6/n-3 fatty acid intake ratio with muscle mass and strength in older adults. This study included 61,381 individuals (28,187 men and 33,194 women) aged โ‰ฅ60...

๐Ÿ—“๏ธ 2025-06-27
๐Ÿ“ฐ Publication: Journal Of Nutrition Health & Aging
Read MoreThe association of n-3 fatty acid intake with muscle mass and strength in older adults: A cross-sectional analysis of the UK biobank data.

AI-based CT assessment of sarcopenia in borderline resectable pancreatic Cancer: A narrative review of clinical and technical perspectives.

Sarcopenia, defined as the progressive loss of skeletal muscle mass and function, has been associated with poor prognosis in patients with pancreatic cancer, particularly those with borderline resectable pancreatic cancer (BRPC). Although body composition can be extracted from routine CT...

๐Ÿ—“๏ธ 2025-06-25
๐Ÿ“ฐ Publication: Computers In Biology And Medicine
Read MoreAI-based CT assessment of sarcopenia in borderline resectable pancreatic Cancer: A narrative review of clinical and technical perspectives.

Sarcosine decreases in sarcopenia and enhances muscle regeneration and adipose thermogenesis by activating anti-inflammatory macrophages.

Age-related changes in circulating metabolites influence systemic physiology and may contribute to diseases such as sarcopenia. Although metabolic dysregulation is closely linked to sarcopenia, the roles of specific metabolites remain unclear. In this study, we performed comprehensive plasma metabolomic and...

๐Ÿ—“๏ธ 2025-06-23
Read MoreSarcosine decreases in sarcopenia and enhances muscle regeneration and adipose thermogenesis by activating anti-inflammatory macrophages.

Ablation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting-Induced Proteolysis.

The neutral amino acid transporter SLC7A8 (LAT2) has been described as a key regulator of metabolic adaptation. LAT2 mutations in human populations have been linked to the early onset of age-related hearing loss and cataract growth. As LAT2 was previously...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAblation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting-Induced Proteolysis.

Association of Alzheimer's Disease Blood Biomarkers With Sarcopenia Incidence and Progression: A 12-Year Population-Based Study.

Sarcopenia is a complex and multifactorial condition, and recent studies have explored the role of neurological markers in its diagnosis and prediction. Although associations have been identified between reduced muscle strength, slow walking speed and elevated neurofilament levels (NfL), long-term...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAssociation of Alzheimer's Disease Blood Biomarkers With Sarcopenia Incidence and Progression: A 12-Year Population-Based Study.

Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

In December 2024, the Society on Cachexia and Wasting Disorders (SCWD) hosted a Regulatory and Trial Update Workshop in Washington, D.C., bringing together experts from academia, industry, and the US Food and Drug Administration (FDA). This article summarizes key topics...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

Ageing Signatures and Disturbed Muscle Regeneration in Muscle Proteome of Inclusion Body Myositis.

Inclusion body myositis (IBM) is the most common acquired myopathy in adults over the age of 50โ€‰years, characterised by inflammatory and degenerative features that lead to progressive muscle weakness and physical disability for lack of effective therapies. The complex interplay...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAgeing Signatures and Disturbed Muscle Regeneration in Muscle Proteome of Inclusion Body Myositis.

Umbelliferone attenuates diabetic sarcopenia by modulating mitochondrial quality and the ubiquitin-proteasome system.

Sarcopenia, characterized by the progressive loss of skeletal muscle mass, strength, and physical performance, is traditionally associated with aging. However, chronic conditions such as type 2 diabetes mellitus (T2DM) have been recognized as key accelerators of its progression. In this...

๐Ÿ—“๏ธ 2025-05-31
๐Ÿ“ฐ Publication: Phytomedicine
Read MoreUmbelliferone attenuates diabetic sarcopenia by modulating mitochondrial quality and the ubiquitin-proteasome system.

Sarcopenia, Muscle Mass and Protein Intake in Adults Older Than 65โ€‰Years After Earlier Bariatric Surgery.

Metabolic and bariatric surgery (MBS) is a proven treatment for obesity. Yet weight loss is accompanied by loss of muscle which may predispose to sarcopenia. The prevalence of low muscle mass in older adults after MBS remains unexplored, even though...

๐Ÿ—“๏ธ 2025-06-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSarcopenia, Muscle Mass and Protein Intake in Adults Older Than 65โ€‰Years After Earlier Bariatric Surgery.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!